FDA Drafts Faster Gene Therapy Approvals

The FDA on Oct. 27 released draft guidance that could speed approval of some gene-editing treatments built for a single patient’s genetic mutation, a step rare disease families have pushed for since a Philadelphia infant received the first personalized CRISPR-based therapy last year. The guidance outlines how one biologics license application, or BLA, could cover many patient-specific versions of a therapy. Under the plan, a new version that falls within preset limits could be added using laboratory data instead of a new clinical trial. The document is a draft open for public comment, and it does not approve any treatment.

A Unified Approval Process for Multiple Variants

The draft, titled Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management, centers on a concept the FDA calls the Individualized Feature Space. According to the Department of Health and Human Services, it is a set of predefined boundaries describing how a gene-editing product may vary from patient to patient while staying under a single approval. When a new patient’s version fits within those boundaries and lab tests show adequate safety and activity, a company could add it to the existing approval without another trial. The draft guidance also covers manufacturing, testing for unintended genetic changes, and labeling.

The scope is narrow. The guidance applies to individualized gene-editing products for diseases caused by a single gene with known disease-causing variants, where each version is designed to achieve the same editing result. Andrew Byrnes, director of one of the FDA’s gene therapy divisions, said during an agency webinar that the document fills a critical gap, according to the Regulatory Affairs Professionals Society. He described requiring a separate application for each patient’s version as infeasible and unnecessary. The guidance builds on earlier drafts, including ones on gene-editing safety testing and the FDA’s plausible mechanism approach.

Karim Mikhail, director of the FDA’s Center for Biologics Evaluation and Research, said the guidance offers “a clear and scientifically rigorous framework for BLA submission and postapproval management.”

Reaction from Patient Advocacy Groups

The patients in view are people with rare inherited disorders in which different families carry different mutations in the same gene. One example is the urea cycle disorder that affected KJ Muldoon, the infant treated at Children’s Hospital of Philadelphia with a therapy designed for his specific variant.

Until now, the path for repeating that success has been unclear. In February, the FDA issued draft guidance on its plausible mechanism pathway, which describes how such therapies could show effectiveness without large randomized trials. The new draft addresses how many patient-specific versions could fall under one approval.

Rare disease advocates welcomed the shift. Paul Scribner, vice president of community programs and education at the PKD Foundation, said the draft is like “putting a flag in the ground and saying, ‘This is important,'” according to STAT.

The guidance arrived 13 days after the FDA launched a Rare Disease Framework Initiative meant to make its evidence standards more consistent. Analysts at RBC Capital Markets who attended a rare disease summit in Washington said they came away more positive about the regulatory outlook, BioSpace reported.

Beyond Approval: The Challenge of Accessibility

While the guidance marks a step forward, approval is only part of the problem. Gene therapies often cost millions of dollars, which can put them out of reach even when they exist.

Alongside the guidance, the Centers for Medicare & Medicaid Services said it will expand its Cell and Gene Therapy Access Model beyond sickle cell disease. Through the voluntary model, CMS negotiates outcomes-based agreements with drugmakers on behalf of state Medicaid programs. The agency plans to invite applications in the coming months.

“A medical breakthrough only matters to patients if they can get it,” CMS Administrator Dr. Mehmet Oz said in the HHS announcement.

The guidance has real limits. Draft guidance is not binding and can change after public comment. A company would still need clinical evidence to win its first approval before adding new variants. And relying more on lab data for each new patient puts heavy weight on testing for unintended edits, which the FDA identifies as a key safety concern.

The guidance also does not create new treatments by itself. Most families with rare genetic diseases will not have access to a personalized therapy soon, and it remains uncertain how many companies will invest in products that may each treat only a handful of patients.